A Case-Control Study Indicates that no Association Exists Between Polymorphisms of IL-33 and IL-1RL1 and Preeclampsia

Background/Aims: Preeclampsia (PE) is a systemic inflammatory response syndrome involving varieties of cytokines, and previous studies have shown that IL-33 and its receptor IL-1RL1 play pivotal roles in the development of it. As a polygenetic hereditary disease, it is necessary to study the gene analysis for PE. Therefore, the present study was to determine whether IL-33 rs3939286 and IL-1RL1 rs13015714 associated with susceptibility to PE in Chinese Han women. Methods: 1,031 PE patients and 1,298 controls were enrolled and the genotyping for rs3939286 in IL-33 and rs13015714 in IL-1RL1 was performed by TaqMan allelic discrimination real-time PCR. Hardy-Weinberg equilibrium (HWE) was examined to ensure the group representativeness and Pearson's chi-square test was used to compare the differences in genetic distributions between the two groups. Results: No significant differences in genotypic and allelic frequencies of the two polymorphisms loci were observed between cases and controls. There were also no significant differences in genetic distributions between mild/severe and early/late-onset PE and control groups. Conclusion: Although our data suggested that the polymorphisms of IL-33 rs3939286 and IL-1RL1 rs13015714 might not be critical risk factors for PE in Chinese Han women, the results need to be validated in different nations.

[1]  T. Macdonald,et al.  The IL-33/ST2 axis: Role in health and disease. , 2015, Cytokine & growth factor reviews.

[2]  Javier Martín,et al.  Protective Role of the Interleukin 33 rs3939286 Gene Polymorphism in the Development of Subclinical Atherosclerosis in Rheumatoid Arthritis Patients , 2015, PloS one.

[3]  Mauricio Campos-Mora,et al.  Alarmin’ Immunologists: IL-33 as a Putative Target for Modulating T Cell-Dependent Responses , 2015, Front. Immunol..

[4]  V. Sandrim,et al.  NLRP1 L155H Polymorphism is a Risk Factor for Preeclampsia Development , 2015, American journal of reproductive immunology.

[5]  A. Hamzaoui,et al.  Interleukin-33 and Behçet disease: Another cytokine among others. , 2015, Human immunology.

[6]  M. Zhong,et al.  Activation of PAR-1/NADPH Oxidase/ROS Signaling Pathways is Crucial for the Thrombin-Induced sFlt-1 Production in Extravillous Trophoblasts: Possible Involvement in the Pathogenesis of Preeclampsia , 2015, Cellular Physiology and Biochemistry.

[7]  A. Teixeira-Carvalho,et al.  Severe preeclampsia: association of genes polymorphisms and maternal cytokines production in Brazilian population. , 2015, Cytokine.

[8]  Jing Zheng,et al.  Decreased Maternal Serum 2-Methoxyestradiol Levels are Associated with the Development of Preeclampsia , 2014, Cellular Physiology and Biochemistry.

[9]  Shiguo Liu,et al.  Interleukin-1β-31C/T and -511T/C Polymorphisms Were Associated with Preeclampsia in Chinese Han Population , 2014, PloS one.

[10]  F. V. Álvarez,et al.  New biomarkers in diagnosis of early onset preeclampsia and imminent delivery prognosis , 2014, Clinical chemistry and laboratory medicine.

[11]  Can Rui,et al.  CDX2 Enhances HTR-8/SVneo Trophoblast Cell Invasion by Altering the Expression of Matrix Metalloproteinases , 2014, Cellular Physiology and Biochemistry.

[12]  P. Žúbor,et al.  TNF-α G308A Gene Polymorphism Has an Impact on Renal Function, Microvascular Permeability, Organ Involvement and Severity of Preeclampsia , 2014, Gynecologic and Obstetric Investigation.

[13]  F. Stamatian,et al.  Maternal/newborn VEGF-C936T interaction and its influence on the risk, severity and prognosis of preeclampsia, as well as on the maternal angiogenic profile , 2014, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[14]  Jing Li,et al.  Genetic variations in IL1A and IL1RN are associated with the risk of preeclampsia in Chinese Han population , 2014, Scientific Reports.

[15]  Janet Moore,et al.  A prospective study of maternal, fetal and neonatal deaths in low- and middle-income countries. , 2014, Bulletin of the World Health Organization.

[16]  S. Illanes,et al.  Innate Immune System and Preeclampsia , 2014, Front. Immunol..

[17]  T. Mazza,et al.  Impact of genetic polymorphisms on the pathogenesis of idiopathic achalasia: Association with IL33 gene variant. , 2014, Human immunology.

[18]  H. Yaghootkar,et al.  Tumor Necrosis Factor-Alpha Polymorphism at Position -238 in Preeclampsia , 2014, Iranian Red Crescent medical journal.

[19]  D. Cheng,et al.  Vascular Endothelial Growth Factor +936C/T, –634G/C, –2578C/A, and –1154G/A Polymorphisms with Risk of Preeclampsia: A Meta-Analysis , 2013, PloS one.

[20]  S. Lydersen,et al.  Mediators of the association between pre-eclampsia and cerebral palsy: population based cohort study , 2013, BMJ.

[21]  Roberto Lardoeyt,et al.  Contribution of genome-environment interaction to pre-eclampsia in a Havana Maternity Hospital. , 2013, MEDICC review.

[22]  R. Mori,et al.  Moving beyond essential interventions for reduction of maternal mortality (the WHO Multicountry Survey on Maternal and Newborn Health): a cross-sectional study , 2013, The Lancet.

[23]  A. Andriulli,et al.  Associations between Genetic Polymorphisms in IL-33, IL1R1 and Risk for Inflammatory Bowel Disease , 2013, PloS one.

[24]  R. Romero,et al.  Maternal plasma concentrations of sST2 and angiogenic/anti-angiogenic factors in preeclampsia , 2013, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[25]  I. Sargent,et al.  ST2 and IL-33 in Pregnancy and Pre-Eclampsia , 2011, PloS one.

[26]  N. Gomez‐Lopez,et al.  An immunological insight into the origins of pre-eclampsia. , 2010, Human reproduction update.

[27]  D. Lambrechts,et al.  Genetic evidence for a role of IL33 in nasal polyposis , 2010, Allergy.

[28]  J. Folkman,et al.  Maternal preeclampsia predicts the development of bronchopulmonary dysplasia. , 2010, The Journal of pediatrics.

[29]  Dirk E. Smith,et al.  Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. , 2009, Arthritis and rheumatism.

[30]  T. Cindrova-Davies.  Gabor Than Award Lecture 2008: pre-eclampsia - from placental oxidative stress to maternal endothelial dysfunction. , 2009, Placenta.

[31]  Richard T. Lee,et al.  The IL-33/ST2 pathway: therapeutic target and novel biomarker , 2008, Nature Reviews Drug Discovery.

[32]  I. McInnes,et al.  IL-33 exacerbates antigen-induced arthritis by activating mast cells , 2008, Proceedings of the National Academy of Sciences.

[33]  C. Maccalman,et al.  Decidual NK Cells Alter In Vitro First Trimester Extravillous Cytotrophoblast Migration: A Role for IFN-γ1 , 2006, The Journal of Immunology.

[34]  Diagnosis and management of preeclampsia and eclampsia , 2002 .

[35]  D. Darmochwal-Kolarz,et al.  The critical role of Th17 cells, Treg cells and co-stimulatory molecules in the development of pre-eclampsia. , 2014, Developmental period medicine.

[36]  ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. , 2002, Obstetrics and gynecology.

[37]  Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. , 2000, American journal of obstetrics and gynecology.